Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
The use of CDK4/6 inhibitors in the treatment of a wide range of cancers is an area of ongoing investigation. Despite their increasing clinical use, there is limited understanding of the determinants of sensitivity and resistance to these drugs. Recent data have cast doubt on how CDK4/6 inhibitors a...
Guardado en:
Autores principales: | Betheney R. Pennycook, Alexis R. Barr |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
The Royal Society
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0c9ea1421674436780d21724cf39f9ba |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab M, et al.
Publicado: (2016) -
Regulation of p27 and Cdk2 Expression in Different Adipose Tissue Depots in Aging and Obesity
por: Ignacio Colón-Mesa, et al.
Publicado: (2021) -
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida M, et al.
Publicado: (2020) -
Functional characterization of CDK10 and cyclin M truncated variants causing severe developmental disorders
por: Thomas Robert, et al.
Publicado: (2021) -
Sensitivity and Specificity of P16 Immunohistochemistry in Diagnosis of Dysplastic Neoplastic Changes in Cervix
por: M Sharbatdaran,, et al.
Publicado: (2009)